Introduction {#Sec1}
============

Despite advances in supportive care, the outcome of patients with acute myeloid leukaemia (AML) remains poor with only about 40 % of adults under 60 years of age achieving long-term survival, and in those over 60 years of age, less than 20 % achieve long-term survival \[[@CR1]\]. Immunotherapeutic strategies, utilising antibodies against tumour antigens, have proved highly effective in other haematological malignancies \[[@CR2]\] but have yet to become established as standard of care in the management of AML. CD33 is frequently expressed on the surface of AML cells and is rarely expressed outside of the haematological system \[[@CR3]\]. Two anti-CD33 antibodies have been evaluated in randomised clinical trials: lintuzumab and gemtuzumab ozogamicin (GO, trade name, Mylotarg). GO is a humanised monoclonal antibody against CD33, conjugated to calicheamicin. Calicheamicin cleaves sequence-specific DNA regions causing double-stranded breaks \[[@CR4]\]. GO was reported to improve overall responses dramatically in adults with relapsed AML \[[@CR5]\], and as a consequence, GO was given accelerated approval by the US Food and Drug Agency in 2000 but was subsequently voluntarily withdrawn in 2010 because of reports of excessive toxicity \[[@CR6]\].

Given the conflicting results of different studies and the potential importance of this drug, the aim of this systematic review and meta-analysis is to assess the totality of the evidence on the effectiveness and optimal delivery of anti-CD33 antibody treatment in AML.

Methods {#Sec2}
=======

Protocol and eligibility {#Sec3}
------------------------

A study protocol was drawn up prior to the review being undertaken. We sought to include all randomised controlled trials (RCTs) that included any patient with AML, where one arm included anti-CD33 antibody therapy. AML could be in any form: de novo or secondary. Previous treatment was not an excluding factor. There were no age restrictions. We considered all examples of anti-CD33 antibody treatment, with or without conjugation to other molecules, for example toxins. Differing doses and regimens of the treatment did not result in exclusion in this review.

Search strategy, sources and inclusion criteria {#Sec4}
-----------------------------------------------

Searches, developed in consultation with an information specialist, were conducted in MEDLINE (1946--2013), Embase (1974--2013) and the Cochrane Library up to December 2013. Major conference proceedings abstracts---American Society of Hematology (ASH) (2004--2013), European Hematology Association (EHA) (2006--2013) and American Society of Clinical Oncology (ASCO) (1996--2013)---were also searched for unpublished trials. Research registers (ClinicalTrials.gov, controlled trials.com, ISRCTN) were searched for ongoing trials. There were no language restrictions. Search strategies are available from the online data supplement.

Studies retrieved from the database searches were reviewed independently by two people (JL and JK or JW), using title and abstract to make inclusion/exclusion decisions. Full paper copies were obtained for further review where there were uncertainties. Disagreement regarding inclusion was resolved by a third member of the team (JW or JK). The selection pathway (Fig. [1](#Fig1){ref-type="fig"}) is presented using a PRISMA flow diagram \[[@CR7]\].Fig. 1Flow diagram of search strategy (according to PRISMA guidelines)

Quality assessment and data extraction {#Sec5}
--------------------------------------

Data was extracted by JL and JK or JW independently using a standardised extraction form. The standardised form included details of trial identification details, population characteristics, details of intervention and control treatments, and outcomes. Outcomes were defined by internationally recognised criteria \[[@CR8]\] and included overall survival (OS), relapse-free survival (RFS), death in complete remission (DCR), cumulative incidence of relapse (CIR), induction death (ID), resistant disease (RD) and response. Variations in outcome definitions between studies are outlined in the online data supplement. Toxicity data was extracted on a standardised form (JL) and reviewed by JW.

Two reviewers (JL and JK or JW) independently assessed each trial for risk of bias utilising the risk of bias tool developed by the Cochrane Collaboration \[[@CR9]\].

Statistical analysis {#Sec6}
--------------------

Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated for dichotomous outcomes. Time-to-event data was extracted using standard methods from Tierney \[[@CR10]\] and Parmar \[[@CR11]\]. Observed minus expected (O − E) number of events and variance were calculated from hazard ratios (HR), CIs, *p* values and survival proportions where available.

Fixed effect meta-analysis methods were used with the *I*^2^ test for statistical heterogeneity performed. Tests for heterogeneity and trend across predefined subgroups were also performed; these subgroups included age, diagnosis, cytogenetic risk group, *FLT3*-ITD, *NPM1*, CD33 status, stage of treatment, total cumulative dose, with or without other chemotherapy agents and treatment confounding (whether comparator arm had the same dose of concomitant chemotherapy: yes, no). Results are presented as odds ratios with 95 % CIs for dichotomous endpoints and Peto's odds ratios with 95 % CIs for time-to-event endpoints. Assumptions for outcome data in studies with incomplete reporting, taken after efforts to contact study authors, are stated in the results.

Results {#Sec7}
=======

Search results {#Sec8}
--------------

The search yielded 1974 articles (Fig. [1](#Fig1){ref-type="fig"}). A search of online clinical trial databases suggested four pending trials. One trial was not due for completion until January 2020 (AML SG09-09; ClinicalTrials.gov identifier: NCT00893399) and would fit our inclusion criteria. Another, NCRI AML17 (ISRCTN55675535), is due to be completed July 2014. The other two were sponsored by pharmaceutical companies; one was terminated early, and the second did not have available data (further supplementary [5](#MOESM1){ref-type="media"}).

Two different anti-CD33 therapies were identified in this systematic review: GO, a humanised monoclonal antibody against CD33 conjugated to a toxin, and lintuzumab, a humanised anti-CD33 monoclonal antibody not conjugated to a toxin. Two trials involving lintuzumab were found \[[@CR12], [@CR13]\] but only one provided sufficient data for analysis of overall survival; this study \[[@CR13]\] did not demonstrate a significant impact of lintuzumab on overall survival (HR = 0.94, 95 % CI = 0.63--1.11); however, this study was small and underpowered. Due to their intrinsic biological differences, these studies were omitted from the main meta-analyses that only involved GO. Thus, 11 trials involving 13 randomisations with 7138 patients entered the meta-analysis of trials involving GO \[[@CR12]--[@CR26]\]. A detailed summary of trials included in this meta-analysis can be found in the supplementary data (further supplementary [4](#MOESM1){ref-type="media"}), with a brief summary of each study described in Table [1](#Tab1){ref-type="table"}. We also excluded two small trials from the meta-analysis because they did not include the same concomitant chemotherapy drugs in the GO and the comparator arm \[[@CR19], [@CR21]\]. Out of the 11 trials, two had a second independent randomisation at a latter treatment stage \[[@CR17], [@CR25]\]. Four studies investigated the use of GO at induction and consolidation phases but with no independent randomisation at the second treatment stage; therefore, these studies contributed to four randomisations only \[[@CR18], [@CR20], [@CR26], [@CR27]\]. Three further randomisations involved the use of GO at induction \[[@CR16], [@CR17], [@CR25]\], two independent randomisations at consolidation \[[@CR17], [@CR24]\] and three at a post-consolidation/maintenance stage \[[@CR22], [@CR23], [@CR25]\]. One trial used GO as part of a low-intensity regimen \[[@CR15]\]. Up-to-date overall survival and relapse data for the NCRI AML15 trial was used from the AML16 publication \[[@CR16]\]. For one study \[[@CR25]\], CIR and DCR were calculated from an interim publication \[[@CR28]\]; data from this interim analysis was used for the induction randomisation of this study.Table 1Summary table of trials included in meta-analysisTrialPopulationMedian ageSizeStageDose (mg/m^2^)Total number of dosesConcomitant chemotherapyControl chemotherapyAmadori 2013APML excluded67472Induction and consolidation6 (induction), 3 (consolidation)2 (induction), 2 (consolidation)MICE (induction), ICE (consolidation)Same concomitant chemotherapy as in GO armBurnett 2011 (induction randomisation)As above491113Induction31DA/ADE/FLAG-IDAAs aboveBurnett 2011 (consolidation randomisation)As above46948Consolidation31MACE/Ara-CAs aboveBurnett 2012 (intensive trial)AML and high-risk MDS671115Induction31DA or [d]{.smallcaps}-Clo at induction (2--3 courses), Aza maintenanceAs aboveBurnett 2012 (low-intensity trial)AML, high-risk MDS75495Low intensityFlat dose of 54Low-dose Ara-C 20 mg s/c injectionAs aboveCastaigne 2012Primary AML62280Induction and consolidation33 (induction), 2 (consolidation)DA (1--2 courses at induction); two courses of DA as consolidationAs aboveDelaunay 2011 ASHIntermediate-karyotype AML50254Induction and consolidation62DA induction and MidAC intensive consolidationAs aboveFernandez 2011APML excluded48270Consolidation61NoneNoneGamis 2013 ASHPrimary AML9.91070Induction and consolidation31 (induction), 1 (consolidation)ADE at induction and mitoxantrone/Ara-C at second consolidationSame concomitant chemotherapy as in GO armHasle 2012Standard/high-risk disease in CR1 post-consolidationNot reported120Maintenance52NoneNoneLowenberg 2010APML excluded67232Maintenance63NoneNonePetersdorf 2013 (induction randomisation)As above47595Induction61DA (45 mg/m^2^ daunorubicin)DA (60 mg/m^2^ daunorubicin)Petersdorf 2013 (maintenance randomisation)As aboveNot reported174Maintenance53NoneNone

Risk of bias {#Sec9}
------------

Overall, most publications failed to describe the randomisation and allocation method; without this information, we are unable to assess whether these trials suffered from selection bias. Otherwise, the risk of bias was low for the published trials (supplementary table [1](#MOESM1){ref-type="media"}).

Two trials \[[@CR26], [@CR27]\] were only available in conference proceedings form which limited assessment of risk of bias and data extraction. Of these, one trial \[[@CR27]\] had available data for all outcomes, although assumptions were made for resistant disease and induction death (see further supplementary [3](#MOESM1){ref-type="media"}). The other trial \[[@CR26]\] only provided data for OS and complete remission (CR) rates. Although data was provided for early deaths, it was unclear whether these deaths were induction related or due to disease. Authors of two unpublished trials \[[@CR26], [@CR27]\] were contacted to obtain full trial reports, but additional data was not available for analysis. In comparison, eight of the nine published trials \[[@CR15]--[@CR18], [@CR20], [@CR22]--[@CR25]\] involving GO provided complete OS data. The exception was the post-consolidation randomisation of one trial \[[@CR25]\]. Out of the nine published trials involving GO, one did not provide RFS rates for a separate consolidation randomisation \[[@CR17]\] (further supplementary [2](#MOESM1){ref-type="media"}).

The impact of GO on response rates and resistant disease {#Sec10}
--------------------------------------------------------

All induction phase trials had sufficient data for analysis of CR rates. One non-intensive trial was omitted from this analysis because of the different treatment strategy \[[@CR15]\]. Overall response (OR) rates (CR plus CR with incomplete count recovery (CRi) or platelet recovery (CRp)) were also calculated; two trial results published as abstract form did not have sufficient data for this analysis \[[@CR26], [@CR27]\]. GO does not have a measurable impact on rates of OR, CR nor CRi/p (Fig. [2](#Fig2){ref-type="fig"} and supplementary figure [1](#MOESM1){ref-type="media"}). However, the addition of GO to treatment significantly reduced the rate of resistant disease (failure to eliminate disease) by 23 % (HR = 0.77, 95 % CI = 0.67--0.90, *p* = 0.0009) (Fig. [2](#Fig2){ref-type="fig"}). However, this was at the expense of a statistically significant increase in induction deaths (HR = 1.30, 95 % CI = 1.04--1.63, *p* = 0.02) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Rates of resistant death, induction death and complete remission. Forest plots (Figs. 2, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}): *black squares* and *horizontal lines* represent estimate and 95 % confidence interval, respectively, for each study. *Open diamond* represents pooled estimates for each subgroup or overall outcome

The impact of GO on relapse rates {#Sec11}
---------------------------------

GO improved CIR by 14 % (HR = 0.86, 95 % CI = 0.79--0.93, *p* = 0.0002) (Fig. [3](#Fig3){ref-type="fig"}). This is principally driven by its use in induction treatment where the use of GO reduced the rate of relapse by 19 % (HR = 0.81, 95 % CI = 0.74--0.90, *p* = 0.00003; test for heterogeneity between subtotals *p* = 0.07). GO had no significant influence on the rates of death in CR analysis (HR = 1.11, 95 % CI = 0.91--1.36, *p* = 0.3) (supplementary figure [2](#MOESM1){ref-type="media"}). Thus, the improvements in CIR correlated with an overall improvement in RFS in the overall analysis (HR = 0.90, 95 % CI = 0.84--0.98, *p* = 0.01) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Cumulative incidence of relapse, grouped by treatment stageFig. 4Relapse-free survival, grouped by treatment stage

GO appears to be beneficial in RFS when used as part of remission induction therapy in a subgroup analysis based on treatment stage (HR = 0.86, 95 % CI = 0.79--0.94, *p* = 0.0007). Although the test for heterogeneity between subtotals was borderline (*p* = 0.1), there is a substantial treatment effect seen in induction subgroup. Alongside the significant result for CIR in the setting of remission induction treatment, we explored this subgroup through predefined analyses. Subgroup analysis did not provide clear evidence that effect size of RFS was dependent on the age of patients (median age of trial entrants greater or less than 60), on the cumulative dose (greater or less than 9 mg/m^2^) they received and on whether there was treatment confounding (whether or not the comparative arm had the same dose of accompanying chemotherapy) (test for heterogeneity between subtotals = not significant) (supplementary figures [3--5](#MOESM1){ref-type="media"}).

The effect of GO on overall survival {#Sec12}
------------------------------------

GO had no significant effect on OS (HR = 0.96, 95 % CI = 0.90--1.02, *p* = 0.2) (Fig. [5](#Fig5){ref-type="fig"}), nor was there any evidence for a benefit of GO at any particular treatment stage. However, AML is a heterogeneous condition clinically and by genetic groupings. These analyses were limited by the number of trials involved. However, in one subgroup, there was evidence of benefit from the use of GO in terms of OS: this was in patients with favourable risk cytogenetics (HR = 0.46, 95 % CI = 0.29--0.73, *p* = 0.001) (test for trend between subtotals *p* = 0.02; test for heterogeneity between subtotals *p* = 0.02) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 5Overall survival, grouped by treatment stageFig. 6Overall survival, grouped by cytogenetics, for induction remission trials

GO did not improve OS, in subgroup analyses of induction trials based on age, cumulative dose nor diagnosis (primary vs. secondary AML) (supplementary figures [6--8](#MOESM1){ref-type="media"}). Available data for *FLT3*-ITD and NPM1 analysis was limited to only three trials and was unable to detect a significant influence of these subgroups on OS (data not shown). A subgroup analysis based on treatment confounding was performed (supplementary figure [9](#MOESM1){ref-type="media"}): there was some evidence of greater benefit for the use of GO in trials without confounding chemotherapy (test for heterogeneity *p* = 0.09). There is no evidence that CD33 positivity influences OS of patients treated with GO (supplementary figure [10](#MOESM1){ref-type="media"}).

Toxicity data for GO {#Sec13}
--------------------

We investigated in detail the increased reports of liver toxicity and incidences of severe veno-occlusive disease (VOD) \[[@CR29]\], particularly in the setting of haematopoietic stem cell transplantation \[[@CR30]\]. This is displayed in the supplementary data (supplementary table [2](#MOESM1){ref-type="media"}), alongside measures of treatment-related fatality. Data was available from four trials using induction treatment (with some coupled with consolidation stage), involving a total of 789 patients \[[@CR18], [@CR20], [@CR25], [@CR26]\]. Twelve cases of VOD were reported; however, there was insufficient data available to report the incidence in the control arm. From these trials, there were five fatalities associated with VOD or severe hepatic toxicity when GO was used. Three trials \[[@CR16], [@CR17], [@CR27]\] did not specify the number of cases of VOD in the GO arm but declared there were no difference incidence by comparison of study arm. As described above, there was a significant difference in death during induction (Fig. [2](#Fig2){ref-type="fig"} which was extracted from endpoints defined directly as induction deaths \[[@CR16]--[@CR18], [@CR20], [@CR25], [@CR27]\], with one omitted due to data provided only of early deaths \[[@CR26]\]).

Discussion {#Sec14}
==========

Our findings show that GO has potent anti-leukaemic effects: there is a significant reduction in treatment-resistant disease by 23 % (*p* = 0.0009), but this is at the expense of an increased induction death rate (*p* = 0.02), leading to no improvement in CR rates. The addition of GO to chemotherapy treatment increases RFS by 10 % (*p* = 0.01) by reducing the rate of disease relapse. The reason for the reduction in relapse is difficult to extrapolate from clinical trials, but the ALFA 0701 group has shown that patients treated with gemtuzumab may have a deeper level of remission, as measured by *NPM1* transcript levels \[[@CR34]\].

This systematic review and meta-analysis provides a comprehensive synthesis of the research on the effect of the current anti-CD33 agents on all outcomes, at all treatment stages and age. The meta-analysis of OS and RFS involved 6880 and 4366 patients, respectively. Three meta-analyses \[[@CR31]--[@CR33]\] have recently been published regarding the use of GO with all three concentrating on induction treatment of AML. One study concurs on our finding that GO improves RFS at the expense of early mortality in induction \[[@CR33]\] despite the inclusion of a trial \[[@CR19]\] that we excluded due to the control treatment having a different concomitant chemotherapy regimen to the GO arm. The second review \[[@CR32]\] concurs with our other outcome findings in the induction subgroup analyses (including resistant disease and relapse rates), notably on cytogenetic stratification. In contrast to both reviews, we have included data from more recently published trials \[[@CR20], [@CR27]\] which have added data for an additional 1494 patients, including unique data on the use of GO in induction remission in the paediatric setting. The third meta-analysis \[[@CR31]\] is an individual patient data (IPD) meta-analysis that included five induction trials \[[@CR16]--[@CR18], [@CR25], [@CR26]\]. This also omits the new data \[[@CR20], [@CR27]\] which may be one explanation regarding the differences in conclusions: where in our study we find a statistically significant increase in induction deaths, only 30-day mortality is reported in the IPD meta-analysis from Hills et al., and although there is a trend to favour no GO, this was not statistically significant. Furthermore, whilst they detect a significant improvement in OS in an overall analysis, this is not corroborated by our systematic review and meta-analysis.

The overall effect of GO was seen only in RFS but not in OS. GO improves OS in patients with favourable cytogenetic AML (patients with core-binding factor translocations), with borderline significance for those with intermediate-risk cytogenetics. This suggests that in the treatment of patients with core-binding factor leukaemia, GO should become standard of care. There was insufficient data to comment on the effect of GO on OS in other favourable prognostic groups such as those with NPM1 mutation. This ability to only improve survival in favourable but not poor prognostic AML is in keeping with conventional chemotherapy agents, as opposed to immune-mediated therapies, such as graft-versus-leukaemia effect in allogeneic stem cell transplants which are effective against adverse-risk AML \[[@CR35]\]. One possible reason why GO might improve RFS but not OS in the overall analysis is the presence of salvage treatments and subsequent allogeneic haematopoietic stem cell transplantation (HSCT) as a way of consolidating second remissions \[[@CR36]\].

In our predefined subgroup analysis of age, we used 60 years of age (based on the median age of trial entrants where available) as a threshold. There is no evidence that the benefit of GO is only restricted to younger patients. This is notable: GO was granted early FDA approval because of success in an older age group \[[@CR5]\]. Furthermore, there is a dearth of successful therapeutic options in this cohort of patients with the outlook for elderly patients considerably poorer than for younger patients, even when they are compared in stratified cytogenetic risk groups \[[@CR37]\]. Targeted therapies may be better tolerated than conventional chemotherapy. Below 60 years of age, our systematic review resulted in eight randomisations at meta-analysis, only two of which was applicable in the paediatric setting \[[@CR22], [@CR27]\]. This is a clinical setting for GO that deserves further attention.

Whilst there is no clear evidence that GO is not effective at other treatment stages, the greatest amount of evidence and the clearest evidence of benefit comes from trials in which GO was used in induction, so we concentrated on these for the subgroup analyses. An analysis of GO based on treatment stage showed it is an effective adjunct in the induction treatment of AML. There is currently no evidence to suggest that it is of benefit in use at any other treatment stages; this suggests optimisation of induction trials warrants the greatest attention. The improvement in RFS is clearly seen when GO was used as part of induction therapy, with improvements of 14 % (*p* = 0.0007) detected driven by improvements in relapse rates of 19 % (*p* = 0.00003).

It is of particular interest to note that the trial \[[@CR25]\] which led to withdrawal of GO from the market had a different dose of anthracycline (GO to no GO arm, 45 to 60 mg/m^2^). This stood out on the confounding treatment subgroup analysis, whereas those trials without a confounding treatment had an overall improvement in OS (test for heterogeneity *p* = 0.09). Apart from this potential explanatory factor, there is no clear reason for the heterogeneity observed between induction trials as subgroup analyses did not provide any clear evidence. An initial report of the use of GO in AML delivered a dose of 9 mg/m^2^ \[[@CR5]\]. However, a considerable range in terms of both cycle numbers and doses per cycle was seen in subsequent trials. A recent study \[[@CR18]\] had suggested their highly fractionated protocol allowed the safe administration of a higher cumulative dose of drug and was part of the reason why they saw a notable benefit for GO in their trial. In contrast, in another study, GO was delivered prior to the use of conventional chemotherapy \[[@CR20]\]. This difference in scheduling may be a reason behind the heterogeneity between these two studies seen in our meta-analysis notably in DCR (supplementary figure [2](#MOESM1){ref-type="media"}), RFS by treatment stage (Fig. [4](#Fig4){ref-type="fig"}) and OS by cytogenetics (Fig. [6](#Fig6){ref-type="fig"}). Our study demonstrates that subgroups based on cumulative doses (above and below 9 mg/m^2^) did not show an advantage in OS and RFS for a higher dose. Overall, this suggests that simple increases in the cumulative dose of GO, inevitably associated with higher toxicity, may be unnecessary.

One striking finding was that the benefit of GO was not significantly reliant on CD33 positivity. This analysis was limited by the fact that available published data did not provide outcome data on more detailed CD33 expression stratification, and thus brought together a potentially heterogeneous group. Publications did not detail the size of CD33+/− precursor populations, which is likely to have significant bearing \[[@CR38]\] on anti-CD33 treatment efficacy, as this may determine the presence of a residual clone that may escape targeted therapy.

The diverse settings and regimens in which anti-CD33 agents have been employed likely explain the varying results seen with this agent, which has led to questions regarding the overall efficacy of the treatment. There is clear evidence of the anti-leukaemic effects of anti-CD33 therapy with GO in reducing rates of resistant disease and relapse rates. There is no significant effect on overall OS, although there was an OS benefit, based on cytogenetic analysis, in those with favourable core-binding factor translocations. Given the paucity of new agents in the treatment of this condition, this suggests this drug should not be discarded but further trials are warranted to further optimise the delivery of this drug to allow more patients with AML to benefit from this treatment.
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Supplementary figures and tables (supplementary table 1-2 and supplementary figures 1-10) and further supplementary methods and tables (further supplementary 1-5) are available online. (PDF 1.36 mb)
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